daratumumab

The Week Ahead In Biotech: Spotlight On ESMO Conference
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Flag link:
Mark Your Calendar For These September PDUFA Dates
Mark Your Calendar For These September PDUFA Dates
Yahoo/Benzinga
FDA
Roche
Celgene
Tecentriq
Xeris Pharmaceuticals
Gvoke
Ardelyx
tenapanor
Merck
Pifeltro
Delstrigo
Novo Nordisk
semaglutide
JNJ
Genmab
daratumumab
Invokana
Flag link:
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
daratumumab
patents
Flag link:
Johnson & Johnson Seeks EU and US Label Expansion for Darzalex
Johnson & Johnson Seeks EU and US Label Expansion for Darzalex
Market Realist
JNJ
Janssen
Darzalex
daratumumab
Europe
Multiple Myeloma
Flag link:
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Endpoints
Genmab
daratumumab
Darzalex
Multiple Myeloma
clinical trials
Flag link:
Johnson & Johnson Courting Huge Revenue Potential In Multiple Myeloma Space
Johnson & Johnson Courting Huge Revenue Potential In Multiple Myeloma Space
Seeking Alpha
JNJ
Multiple Myeloma
daratumumab
ASCO 2016
Flag link:
Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen
Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen
Motley Fool
JNJ
FDA
Amgen
Darzalex
daratumumab
Multiple Myeloma
Flag link:
J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex
J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex
Fierce Biotech
JNJ
Multiple Myeloma
daratumumab
FDA
Darzalex
Genmab
Flag link:
4 Things Johnson & Johnson Should Address When it Reports Its Q3 Results
4 Things Johnson & Johnson Should Address When it Reports Its Q3 Results
Motley Fool
JNJ
earnings
Invokana
daratumumab
devices
Flag link:
Bristol-Myers, J&J Upgraded On New Drug Prospects
Bristol-Myers, J&J Upgraded On New Drug Prospects
Investors.com
Bristol-Myers Squibb
JNJ
Imbruvica
Opdivo
daratumumab
Flag link:
J&J positions blockbuster contender daratumumab for a multiple myeloma showdown
J&J positions blockbuster contender daratumumab for a multiple myeloma showdown
Fierce Biotech
JNJ
daratumumab
Multiple Myeloma
Kyprolis
Amgen
Genmab
elotuzumab
AbbVie
Bristol-Myers Squibb
Flag link:
Is This Johnson & Johnson's Next Blockbuster?
Is This Johnson & Johnson's Next Blockbuster?
Investopedia
JNJ
Multiple Myeloma
daratumumab
Flag link:
Genmab shares rise on cancer drug's FDA license application
Genmab shares rise on cancer drug's FDA license application
Yahoo/Reuters
Genmab
FDA
JNJ
daratumumab
Multiple Myeloma
Flag link:
Your ASCO15 guide: A mixed bag for Bristol-Myers, big wins for Merck, J&J
Your ASCO15 guide: A mixed bag for Bristol-Myers, big wins for Merck, J&J
BioPharma Dive
ASCO
Bristol-Myers Squibb
JNJ
Merck
Keytruda
Opdivo
daratumumab
Flag link:
J&J multiple myeloma drug offers hope after others stop working -study
J&J multiple myeloma drug offers hope after others stop working -study
Yahoo/Reuters
JNJ
Multiple Myeloma
ASCO
daratumumab
Flag link:
JNJ launches PhII lymphoma study for daratumumab
JNJ launches PhII lymphoma study for daratumumab
Fierce Biotech
JNJ
lymphoma
daratumumab
Genmab
non-Hodgkin's lymphoma
Flag link:
Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma
Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma
Pipeline Review
daratumumab
Multiple Myeloma
Flag link:
J&J hands over $25M milestone for daratumumab progress
J&J hands over $25M milestone for daratumumab progress
Fierce Biotech
JNJ
daratumumab
Genmab
Flag link:
Milestone payment triggers Genmab guidance increase
Milestone payment triggers Genmab guidance increase
Yahoo/Reuters
Genmab
daratumumab
JNJ
Janssen
Flag link:
These 2 Companies Are the Biggest Winners of the FDA's Breakthrough Designation
These 2 Companies Are the Biggest Winners of the FDA's Breakthrough Designation
Motley Fool
FDA
breakthrough therapies
ibrutinib
Pharmacyclics
JNJ
Novartis
LDK378
serelaxin
daratumumab
Genmab
Flag link:

Pages